BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 24081426)

  • 1. Demonstrating disease activity in patients with rheumatoid arthritis. Is 18F FDG PET a sensitive method?
    Karapolat I; Sertpoyraz F; Oncel G; Kobak S; Yalcin M; Kumanlioglu K
    Nuklearmedizin; 2013 Dec; 52(6):244-9. PubMed ID: 24081426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDG PET Imaging of Extremities in Rheumatoid Arthritis.
    Dhawan R; Lokitz K; Lokitz S; Caldito G; Takalkar AM
    J La State Med Soc; 2016; 168(5):156-161. PubMed ID: 27797345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of Large Joint Destruction in Patients With Rheumatoid Arthritis Using 18F-FDG PET/CT and Disease Activity Score.
    Suto T; Okamura K; Yonemoto Y; Okura C; Tsushima Y; Takagishi K
    Medicine (Baltimore); 2016 Feb; 95(7):e2841. PubMed ID: 26886646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-body FDG-PET/CT on rheumatoid arthritis of large joints.
    Kubota K; Ito K; Morooka M; Mitsumoto T; Kurihara K; Yamashita H; Takahashi Y; Mimori A
    Ann Nucl Med; 2009 Nov; 23(9):783-91. PubMed ID: 19834653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (18)F-FDG and (18)F-NaF PET/CT demonstrate coupling of inflammation and accelerated bone turnover in rheumatoid arthritis.
    Watanabe T; Takase-Minegishi K; Ihata A; Kunishita Y; Kishimoto D; Kamiyama R; Hama M; Yoshimi R; Kirino Y; Asami Y; Suda A; Ohno S; Tateishi U; Ueda A; Takeno M; Ishigatsubo Y
    Mod Rheumatol; 2016; 26(2):180-7. PubMed ID: 26140472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Semi-quantitative analysis of
    Ravikanth R; Singh JK
    World J Nucl Med; 2020; 19(4):347-352. PubMed ID: 33623503
    [No Abstract]   [Full Text] [Related]  

  • 7. F-18 FDG whole-body PET for the assessment of disease activity in patients with rheumatoid arthritis.
    Goerres GW; Forster A; Uebelhart D; Seifert B; Treyer V; Michel B; von Schulthess GK; Kaim AH
    Clin Nucl Med; 2006 Jul; 31(7):386-90. PubMed ID: 16785804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and Validation of an
    Lee SJ; Jeong JH; Lee CH; Ahn BC; Eun JS; Kim NR; Kang JW; Nam EJ; Kang YM
    Arthritis Rheumatol; 2019 Aug; 71(8):1232-1240. PubMed ID: 30771237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of disease activity in rheumatoid arthritis with (18)F-FDG PET.
    Beckers C; Ribbens C; André B; Marcelis S; Kaye O; Mathy L; Kaiser MJ; Hustinx R; Foidart J; Malaise MG
    J Nucl Med; 2004 Jun; 45(6):956-64. PubMed ID: 15181130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of tocilizumab therapy in patients with rheumatoid arthritis based on FDG-PET/CT.
    Okamura K; Yonemoto Y; Okura C; Higuchi T; Tsushima Y; Takagishi K
    BMC Musculoskelet Disord; 2014 Nov; 15():393. PubMed ID: 25417119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors associated with the progression of large-joint destruction in patients with rheumatoid arthritis after biologic therapy: A post-hoc analysis using FDG-PET/CT and the ARASHI (assessment of rheumatoid arthritis by scoring of large-joint destruction and healing in radiographic imaging) scoring method.
    Suto T; Yonemoto Y; Okamura K; Okura C; Kaneko T; Kobayashi T; Tachibana M; Tsushima Y; Takagishi K
    Mod Rheumatol; 2017 Sep; 27(5):820-827. PubMed ID: 27919199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-FDG PET as a tool to predict the clinical outcome of infliximab treatment of rheumatoid arthritis: an explorative study.
    Elzinga EH; van der Laken CJ; Comans EF; Boellaard R; Hoekstra OS; Dijkmans BA; Lammertsma AA; Voskuyl AE
    J Nucl Med; 2011 Jan; 52(1):77-80. PubMed ID: 21149486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical features of atlantoaxial involvement in patients with rheumatoid arthritis using
    Noguchi A; Kurita T; Matsuzawa K
    Clin Rheumatol; 2023 Jul; 42(7):1875-1884. PubMed ID: 37000282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-FDG PET-CT in rheumatoid arthritis patients tapering TNFi: reliability, validity and predictive value.
    Bouman CAM; van Herwaarden N; Blanken AB; Van der Laken CJ; Gotthardt M; Oyen WJG; den Broeder AA; van der Maas A; van den Ende CH
    Rheumatology (Oxford); 2022 Apr; 61(SI):SI6-SI13. PubMed ID: 34791068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of methods of quantifying global synovial metabolic activity with FDG-PET/CT in rheumatoid arthritis.
    Raynor WY; Jonnakuti VS; Zirakchian Zadeh M; Werner TJ; Cheng G; Zhuang H; Høilund-Carlsen PF; Alavi A; Baker JF
    Int J Rheum Dis; 2019 Dec; 22(12):2191-2198. PubMed ID: 31721461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The assessment of biologic treatment in patients with rheumatoid arthritis using FDG-PET/CT.
    Okamura K; Yonemoto Y; Arisaka Y; Takeuchi K; Kobayashi T; Oriuchi N; Tsushima Y; Takagishi K
    Rheumatology (Oxford); 2012 Aug; 51(8):1484-91. PubMed ID: 22513145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose 18F-FDG PET/CT enterography: improving on CT enterography assessment of patients with Crohn disease.
    Shyn PB; Mortele KJ; Britz-Cunningham SH; Friedman S; Odze RD; Burakoff R; Goldberg JE; Erturk M; Silverman SG
    J Nucl Med; 2010 Dec; 51(12):1841-8. PubMed ID: 21078803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical value of ¹⁸F-fluoro-dexoxyglucose positron emission tomography/computed tomography in patients with adult-onset Still's disease: a seven-case series and review of the literature.
    Yamashita H; Kubota K; Takahashi Y; Minamimoto R; Morooka M; Kaneko H; Kano T; Mimori A
    Mod Rheumatol; 2014 Jul; 24(4):645-50. PubMed ID: 24252024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of vitality of liver lesions by alveolar echinococcosis. Comparison of parametric contrast enhanced ultrasound (SonoVue®) with quantified 18F-FDG-PET-CT.
    Kaltenbach TE; Graeter T; Mason RA; Kratzer W; Oeztuerk S; Haenle MM; Gruener B; Gottstein M
    Nuklearmedizin; 2015; 54(1):43-9. PubMed ID: 25423884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma.
    Abe Y; Tamura K; Sakata I; Ishida J; Ozeki Y; Tamura A; Uematsu K; Sakai H; Goya T; Kanazawa M; Machida K
    Oncol Rep; 2012 Feb; 27(2):333-8. PubMed ID: 22024889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.